Samsung’s venture investment arm is exploring a significant new opportunity by aiming to invest in California-based medical device innovator, Exo, in a funding round that could reach up to $100 million. According to industry sources, this potential investment highlights Samsung’s growing interest in advancing healthcare technology through strategic partnerships.
Leading the funding effort are prominent firms such as Sands Capital, Bold Capital, and Qubit Health Capital. Notably, Imar Ishrak, chairman of Qubit, is set to join Exo’s board, signaling a strong commitment from key industry players.
Founded in 2015, Exo has rapidly gained recognition for its groundbreaking handheld medical imaging devices. These innovative tools leverage artificial intelligence, advanced medical imaging, and silicon technology to perform ultrasound examinations—ranging from lung scans to echocardiograms. Designed for convenience, Exo’s devices connect directly to smartphones, enabling healthcare professionals to perform scans, document findings, and share reports seamlessly through a single app.
With over $320 million in funding to date, Exo has attracted investments from major players like RA Capital Management, BlackRock, Intel, Sony, and Avidity Partners. Its recent Series C funding round in 2021 alone brought in $220 million, underscoring strong investor confidence.
In addition to funding pursuits, Exo is actively exploring a strategic partnership with Samsung Medison, a leading manufacturer of ultrasound diagnostics and digital X-ray systems. This potential collaboration could further propel Exo’s innovative medical imaging solutions into the mainstream healthcare market.
While specific comments from Exo, Samsung, and the investment firms remain unavailable, the emerging partnership signals an exciting phase for medical technology innovation. Stay tuned as these industry giants work together to reshape the future of portable and accessible healthcare diagnostics.
